Life Sciences & MOBs: Persistent Demand Amidst Market Shifts

By Majid Radaei, RadCRE · · Market Updates

Life sciences and medical office buildings (MOBs) continue to attract substantial capital, with Q4 2025 seeing an estimated $7.2 billion in transaction volume, demonstrating robust investor appetite.

Resilient Capital Inflows into Healthcare Real Estate

Despite broader commercial real estate headwinds, the life sciences and medical office building (MOB) sectors have demonstrated remarkable resilience, continuing to attract robust investor interest. This sustained demand is driven by demographic shifts, advancements in biotechnology, and the non-discretionary nature of healthcare services. Investors are increasingly viewing these asset classes as defensive plays, offering stable income streams and potential for long-term appreciation.

According to recent reports, transaction volumes for healthcare real estate, encompassing both life sciences and MOBs, remained strong through 2025. Q4 2025 alone witnessed an estimated $7.2 billion in transaction volume across these sectors, according to MSCI Real Assets data. This sustained activity underscores investor confidence in the underlying fundamentals, even as other property types grapple with elevated interest rates and tighter lending conditions.

Life Sciences: Innovation-Driven Growth

The life sciences sector, characterized by research & development labs, biomanufacturing facilities, and specialized office space, continues its expansion, particularly in established hubs like Boston-Cambridge, the Bay Area, and San Diego. These markets benefit from a confluence of academic institutions, venture capital funding, and a highly skilled workforce. For instance, BioMed Realty, a major player in the life sciences space, recently announced significant pre-leasing activity at its developing projects in Cambridge, underscoring the strong tenant demand for state-of-the-art facilities.

Vacancy rates in core life sciences markets remain historically low, typically in the single digits, despite a significant development pipeline. JLL reported Q4 2025 national life sciences vacancy at approximately 8.5%, indicating a competitive leasing environment. Lease rates continue to ascend in prime locations, with some Class A lab spaces in Cambridge commanding upwards of $150 per square foot NNN.

Medical Office Buildings: A Stable Anchor

Medical office buildings offer a different, yet equally compelling, investment thesis centered on stability and recession resistance. Demand for MOBs is primarily driven by an aging population requiring more frequent and specialized medical care. This translates into high tenant retention rates and predictable income streams for landlords. MOBs typically feature long-term leases, often with credit-rated healthcare providers like hospital systems, further enhancing their attractiveness.

Recent transactions highlight this stability. For instance, Physician's Realty Trust (NYSE: DOC) and Healthpeak Properties (NYSE: PEAK) completed their merger in Q1 2026, creating a premier healthcare REIT with a significant MOB portfolio, signaling institutional conviction in the sector's long-term value. Cap rates for MOBs have remained relatively compressed compared to other asset classes, generally ranging from 5.5% to 6.8% for well-located, institutional-quality assets, reflecting their lower risk profile.

Financing Landscape and Opportunities

While debt markets have tightened universally, life sciences and MOB assets often benefit from more favorable lending terms due to their perceived stability. Lenders, including insurance companies and regional banks, view these assets as less susceptible to economic downturns. For instance, bridge loans for stabilized MOBs might see rates of SOFR + 350-450 bps, while Class A life sciences developments could command terms of SOFR + 400-550 bps, depending on sponsor strength and pre-leasing commitments. Agency and CMBS debt are also available for stabilized, cash-flowing properties, though CMBS spreads have fluctuated, with recent offerings for high-quality assets seeing spreads around T + 175-250 bps.

RadCRE Perspective

Majid Radaei, Founder of RAD Commercial Realty, notes, "The divergence in performance between sectors is stark. While traditional office battles structural challenges, life sciences and MOBs embody resilience. We're advising clients to scrutinize the specifics within these sectors. Not all 'life science' assets are created equal; the specific lab fit-out, ventilation systems, power capabilities, and proximity to research institutions like Harvard or Stanford are paramount. Similarly, with MOBs, it’s about tenant mix – is it primary care or specialty? Is the tenant a strong health system with multiple locations, or an independent practice? These nuances are critical for underwriting risk and future value. We're seeing strong competition for truly premier assets, but structured financing solutions, possibly involving mezzanine debt at 12-16% for bridge-to-perm strategies, can unlock value in strong secondary market opportunities or quality value-add plays that might initially be overlooked by core funds. Our focus remains on structuring capital for assets that can command premium yields and demonstrate long-term tenant stickiness, leveraging our network of lenders who understand these specialized sub-sectors."

RadCRE has a strong track record in advising clients on investment sales and financing strategies for specialized asset classes, including hotels, multifamily, and medical office properties. Our team leverages extensive market knowledge and advanced underwriting tools to identify compelling opportunities and structure optimal capital solutions for our clients.

Tags: life sciences real estate, medical office building investment, healthcare real estate, commercial real estate financing, RadCRE, Majid Radaei

Sources: MSCI Real Assets, JLL Research, Commercial Observer, CoStar, Physician's Realty Trust, Healthpeak Properties